구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Talimogene Laherparepvec (Talimogene Laherparepvec) SOLTI Breast Cancer Research Group·Melanoma 48 trials |
|---|---|
Overview Program | Talimogene Laherparepvec |
Overview Company | SOLTI Breast Cancer Research Group |
Overview Modality | CGT |
Overview Target | Melanoma |
Overview Indication | Peritoneal Surface Malignancy |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | , and emerging therapeutic potential of oncolytic viruses (OVs) in the management of HNSCC, with an emphasis on ongoing trials, approved agents, and future directions |
MoA Biomarker | HER2-negative breast cancer follow |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.. Advanced melanoma, a highly lethal skin cancer, causes most skin cancer-related deaths. Oncolytic monotherapy or alongside immune checkpoint inhibitors (ICIs) is emerging as a promising treatment. Evaluating the therapeutic b… |
Clinical Safety signal | Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.. Advanced melanoma, a highly lethal skin cancer, causes most skin cancer-related deaths. Oncolytic monotherapy or alongside immune checkpoint inhibitors (ICIs) is emerging as a promising treatment. Evaluating the therapeutic b… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT03714828 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03714828 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Talimogene Laherparepvec (Talimogene Laherparepvec) SOLTI Breast Cancer Research Group·Melanoma 48 trials |
|---|---|
Overview Program | Talimogene Laherparepvec |
Overview Company | SOLTI Breast Cancer Research Group |
Overview Modality | CGT |
Overview Target | Melanoma |
Overview Indication | Peritoneal Surface Malignancy |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | , and emerging therapeutic potential of oncolytic viruses (OVs) in the management of HNSCC, with an emphasis on ongoing trials, approved agents, and future directions |
MoA Biomarker | HER2-negative breast cancer follow |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.. Advanced melanoma, a highly lethal skin cancer, causes most skin cancer-related deaths. Oncolytic monotherapy or alongside immune checkpoint inhibitors (ICIs) is emerging as a promising treatment. Evaluating the therapeutic b… |
Clinical Safety signal | Re-evaluating melanoma treatment: a comparative look at herpes simplex virus and coxsackievirus oncolytic therapies in advanced melanoma: a meta-analysis of clinical trials.. Advanced melanoma, a highly lethal skin cancer, causes most skin cancer-related deaths. Oncolytic monotherapy or alongside immune checkpoint inhibitors (ICIs) is emerging as a promising treatment. Evaluating the therapeutic b… |
Clinical Selected reported efficacy | ORR 100% |
Clinical Reported ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT03714828 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03714828 |
추천 비교
추천 비교